Elanco Animal Health Incorporated (ELAN)
USD 11.73
(-4.71%)
USD 11.73
(-4.71%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.13 Billion USD | -0.77% |
| 2022 | 8.2 Billion USD | -8.31% |
| 2021 | 8.94 Billion USD | -2.95% |
| 2020 | 9.21 Billion USD | 168.02% |
| 2019 | 3.43 Billion USD | -8.52% |
| 2018 | 3.75 Billion USD | 227.03% |
| 2017 | 1.14 Billion USD | 7.25% |
| 2016 | 1.07 Billion USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 7.96 Billion USD | -2.16% |
| 2024 Q2 | 7.82 Billion USD | -1.77% |
| 2023 FY | 8.13 Billion USD | -0.77% |
| 2023 Q1 | 8.28 Billion USD | 1.06% |
| 2023 Q2 | 8.37 Billion USD | 1.05% |
| 2023 Q3 | 8.21 Billion USD | -1.98% |
| 2023 Q4 | 8.13 Billion USD | -0.86% |
| 2022 Q2 | 8.46 Billion USD | -2.06% |
| 2022 FY | 8.2 Billion USD | -8.31% |
| 2022 Q4 | 8.2 Billion USD | -0.01% |
| 2022 Q3 | 8.2 Billion USD | -3.05% |
| 2022 Q1 | 8.63 Billion USD | -3.42% |
| 2021 Q2 | 8.85 Billion USD | -1.43% |
| 2021 Q3 | 8.88 Billion USD | 0.34% |
| 2021 FY | 8.94 Billion USD | -2.95% |
| 2021 Q4 | 8.94 Billion USD | 0.7% |
| 2021 Q1 | 8.98 Billion USD | -2.56% |
| 2020 Q1 | 3.06 Billion USD | -10.85% |
| 2020 Q2 | 3.22 Billion USD | 5.17% |
| 2020 Q3 | 8.89 Billion USD | 175.82% |
| 2020 FY | 9.21 Billion USD | 168.02% |
| 2020 Q4 | 9.21 Billion USD | 3.64% |
| 2019 Q4 | 3.43 Billion USD | 3.08% |
| 2019 Q1 | 3.55 Billion USD | -5.53% |
| 2019 Q3 | 3.33 Billion USD | -7.11% |
| 2019 FY | 3.43 Billion USD | -8.52% |
| 2019 Q2 | 3.59 Billion USD | 1.13% |
| 2018 Q1 | - USD | -100.0% |
| 2018 FY | 3.75 Billion USD | 227.03% |
| 2018 Q4 | 3.75 Billion USD | -7.74% |
| 2018 Q3 | 4.07 Billion USD | 311.22% |
| 2018 Q2 | 990.8 Million USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | 1.14 Billion USD | 0.0% |
| 2017 FY | 1.14 Billion USD | 7.25% |
| 2016 FY | 1.07 Billion USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 3.45 Billion USD | -135.738% |
| Bausch Health Companies Inc. | 27.43 Billion USD | 70.33% |
| Catalent, Inc. | 6.14 Billion USD | -32.363% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -586.488% |
| Perrigo Company plc | 6.04 Billion USD | -34.725% |
| Teva Pharmaceutical Industries Limited | 35.35 Billion USD | 76.978% |
| Zoetis Inc. | 9.29 Billion USD | 12.437% |